Loading clinical trials...
Loading clinical trials...
A Phase II Study of JS212 in Combination With JS111 in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
JS212 for Injection＋JS111 capsules (AP-L1898)
Locations
2
China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Start Date
March 23, 2026
Primary Completion Date
April 23, 2028
Completion Date
April 23, 2029
Last Updated
April 8, 2026
Lead Sponsor
Shanghai Junshi Bioscience Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions